Silke Tello

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Andreas Güenther, Ekaterina Krauss, Silke Tello et al. · Respiratory Research · 2018 · 243 citations · Full text

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)

Ekaterina Krauss, Godja Von Gehrken, Fotios Drakopanagiotakis et al. · BMC Pulmonary Medicine · 2019 · 50 citations · Full text

Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)

Ekaterina Krauss, Mustapha El-Guelai, Joern Pons-Kuehnemann et al. · Journal of Clinical Medicine · 2020 · 27 citations · Full text

Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)

Andreas Güenther, Antje Prasse, Michael Kreuter et al. · 2019 · 20 citations

Acute Lung Injury, Non-ipf Lung Fibrosis, Antifibrotic Therapy +19